Suloctidil

Suloctidil was a sulfur-containing aminoalcohol that was brought to market in the early 1970s as a vasodilator by Continental Pharma, a Belgian company.[1]:118–121[2][3]

Suloctidil
Clinical data
ATC code
Identifiers
CAS Number
PubChem CID
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.053.920
Chemical and physical data
FormulaC20H35NOS
Molar mass337.563 g·mol−1
  (verify)

Continental was bought by Monsanto in 1984, primarily on the promise of sales of suloctidil, which was approved in Europe at the time, but not in the US.[4] However, in 1985 Monsanto halted development and withdrew the drug worldwide following reports of liver toxicity.[5]:251

References
  1. Hladovec J (1989). Antithrombotic Drugs in Thrombosis Models. CRC Press. ISBN 9780849351624.
  2. Roncucci R, Roba J, Lambelin G, Ferenczi M, Blaton V, Vandamme D, Peeters H (March 1975). "Potential antilipolytic activity of suloctidil". Die Naturwissenschaften. 62 (3): 141–2. Bibcode:1975NW.....62..141R. doi:10.1007/bf00623284. PMID 1240601.
  3. BE granted 739678, Buu-Hoi NP, Lambelin G, Roba J, Jacques G, Gillet C, "1-Subst-phenyl-2-amino-ethanols useful as beta adrenergic agents peripheral vasodilators and hypotensive agents"
  4. Staff (5 November 1984). "Monsanto's $150 mil. Life Sciences Research Center". The Pink Sheet.CS1 maint: uses authors parameter (link)
  5. "Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or not Approved by Governments Twelfth Issue: Pharmaceuticals" (PDF). Department of Economic and Social Affairs of the United Nations Secretariat. New York: United Nations. 2005.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.